showed that SMARCA4 through synergies with lack of p53 and KRAS activation plays a role of tumor suppressor, and these SMARCA4 mutations in the tumor were highly sensitive to the inhibition of oxidative phosphorylation (160). This evidence concerns the gene SMARCA4 and neoplasm.